Advertisement

Biological testing for drugs of abuse

  • David Vearrier
  • John A. Curtis
  • Michael I. Greenberg
Part of the Experientia Supplementum book series (EXS, volume 100)

Abstract

Testing for drugs of abuse has become commonplace and is used for a variety of indications. Commonly employed testing methods include immunoassay and chromatography. Testing methods vary in their sensitivity, specificity, time, and cost. While urine remains the most common body fluid used for testing of drugs of abuse, over the last several decades the use of alternative matrices such as blood, sweat, oral fluids, and hair has increased dramatically. Each biological matrix offers advantages and disadvantages for drug testing, and the most appropriate matrix frequently depends on the indications for the drug test. Drugs of abuse that are most commonly tested include alcohol, amphetamines, cannabinoids, cocaine, opiates, and phencyclidine. Testing may involve detection of the parent compound or metabolites and sensitivity, specificity, and reliability of drug testing may vary depending on the drug being tested. Toxicologists have a responsibility to understand the strengths and limitations of testing techniques and matrices to be able to critically evaluate the results of a drug test.

Keywords

Drug Testing Oral Fluid Fatty Acid Ethyl Ester External Contamination Sweat Testing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mulé, SJ, Jukofsky D, Kogan M, De Pace A, Verebey K (1977) Evaluation of the radioimmunoassay for benzoylecgonine (a cocaine metabolite) in human urine. Clin Chem 23: 796–801PubMedGoogle Scholar
  2. 2.
    Dolan K, Rouen D, Kimber J (2004) An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug Alcohol Rev 23: 213–217CrossRefPubMedGoogle Scholar
  3. 3.
    Smith-Kielland A, Skuterud B, M-rland J (1999) Urinary excretion of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 23: 323–332PubMedGoogle Scholar
  4. 4.
    Kraemer T, Paul LD (2007) Bioanalytical procedures for determination of drugs of abuse in blood. Anal Bioanal Chem 388: 1415–1435CrossRefPubMedGoogle Scholar
  5. 5.
    Moeller MR, Kraemer T (2002) Drugs of abuse monitoring in blood for control of driving under the influence of drugs. Ther Drug Monit 24: 210–221CrossRefPubMedGoogle Scholar
  6. 6.
    Kroener L, Musshoff F, Madea B (2003) Evaluation of immunochemical drug screenings of whole blood samples. A retrospective optimization of cut off levels after confirmation-analysis on GC-MS and HPLC-DAD. J Anal Toxicol 27: 205–212PubMedGoogle Scholar
  7. 7.
    Spiehler V, Isenschmid DS, Matthews P, Kemp P, Kupiec T (2003) Performance of a microtiter plate ELISA for screening of postmortem blood for cocaine and metabolites. J Anal Toxicol 27: 587–591PubMedGoogle Scholar
  8. 8.
    Bernhoft IM, Steentoft A, Johansen SS, Klitgaard NA, Larsen LB, Hansen LB (2005) Drugs in injured drivers in Denmark. Forensic Sci Int 150: 181–189CrossRefPubMedGoogle Scholar
  9. 9.
    Drummer OH (2005) Pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int 150: 133–142CrossRefPubMedGoogle Scholar
  10. 10.
    Drummer OH (2008) Introduction and review of collection techniques and applications of drug testing of oral fluid. Ther Drug Monit 30: 203–206PubMedGoogle Scholar
  11. 11.
    O’Neal CL, Crouch DJ, Rollins DE, Fatah AA (2000) The effects of collection methods on oral fluid codeine concentrations. J Anal Toxicol 24: 536–542PubMedGoogle Scholar
  12. 12.
    Crouch DJ, Walsh JM, Flegel R, Cangianelli L, Baudys J, Atkins R (2005) An evaluation of selected oral fluid point-of-collection drug-testing devices. J Anal Toxicol 29: 244–248PubMedGoogle Scholar
  13. 13.
    Walsh JM, Flegel R, Crouch DJ, Cangianelli L, Baudys J (2003) An evaluation of rapid point-of-collection oral fluid drug-testing devices. J Anal Toxicol 27: 429–439PubMedGoogle Scholar
  14. 14.
    Aps JK, Martens LC (2005) The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 150: 119–131CrossRefPubMedGoogle Scholar
  15. 15.
    Teixeira H, Proenca P, Verstraete A, Corte-Real F, Vieira DN (2005) Analysis of Δ9-tetrahydrocannabinol in oral fluid samples using solid-phase extraction and high-performance liquid chromatography-electrospray ionization mass spectrometry. Forensic Sci Int 150: 205–211CrossRefPubMedGoogle Scholar
  16. 16.
    Crouch DJ (2005) Oral fluid collection: The neglected variable in oral fluid testing. Forensic Sci Int 150: 165–173CrossRefPubMedGoogle Scholar
  17. 17.
    Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, Perez-Reyes M (1993) Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21: 717–723PubMedGoogle Scholar
  18. 18.
    Huestis MA, Oyler JM, Cone EJ, Wstadik AT, Schoendorfer D, Joseph RE Jr (1999) Sweat testing for cocaine, codeine and metabolites by gas chromatography—mass spectrometry. J Chromatogr B Biomed Sci Appl 733: 247–264CrossRefPubMedGoogle Scholar
  19. 19.
    Liberty HJ, Johson BD, Fortner N, Randolph D (2003) Detecting crack and other cocaine use with fastpatches. Addict Biol 8: 191–200CrossRefPubMedGoogle Scholar
  20. 21.
    Kidwell DA, Holland JC, Athanaselis S (1998) Testing for drugs of abuse in saliva and sweat. J Chromatogr B Biomed Sci Appl 713: 111–135CrossRefPubMedGoogle Scholar
  21. 22.
    Kintz P (1996) Drug testing in addicts: A comparison between urine, sweat, and hair. Ther Drug Monit 18: 450–455CrossRefPubMedGoogle Scholar
  22. 23.
    Cone EJ, Hillsgrove MJ, Jenkins AJ, Keenan RM, Darwin WD (1994) Sweat testing for heroin, cocaine, and metabolites. J Analyt Toxicol 18: 298–305Google Scholar
  23. 24.
    Kintz P, Tracqui A, Mangin P, Edel Y (1996) Sweat testing in opioid users with a sweat patch. J Analyt Toxicol 20: 393–397Google Scholar
  24. 25.
    Kintz P, Tracqui A, Marzullo C, Darreye A, Tremeau F, Greth P, Ludes B (1998) Enantioselective analysis of methadone in sweat as monitored by liquid chromatography/ion spray-mass spectrometry. Ther Drug Monit 20: 35–40CrossRefPubMedGoogle Scholar
  25. 26.
    United States of America v. Jamie M. Snyder (2002) 5: 99-CR-528 (HGM/GJD), US District Court Northern District of New York [http://www.drugpolicy.org/docUploads/usv_snyder.pdf]Google Scholar
  26. 27.
    Kidwell DA, Smith FP (2001) Susceptibility of PharmChek drugs of abuse patch to environmental contamination. Forensic Sci Int 116: 89–106CrossRefPubMedGoogle Scholar
  27. 28.
    Levisky JA, Bowerman DL, Jenkins WW, Karch SB (2000) Drug deposition in adipose tissue and skin: Evidence for an alternative source of positive sweat patch tests. Forensic Sci Int 110: 35–46CrossRefPubMedGoogle Scholar
  28. 29.
    Balabanova S, Schneider E, Wepler R, Hermann B, Boschek HJ, Scheitler H (1992) [Significance of drug determination in pilocarpine sweat for detection of past drug abuse]. Beitr Gerichtl Med 50: 111–115PubMedGoogle Scholar
  29. 30.
    Curtis J, Greenberg M (2008) Screening for drugs of abuse: Hair as an alternative matrix: A review for the medical toxicologist. Clin Toxicol (Phila) 46: 22–34Google Scholar
  30. 31.
    Society of Hair Testing (2004) Recommendations for hair testing in forensic cases. Forensic Sci Int 145: 83–84CrossRefGoogle Scholar
  31. 32.
    Baumgartner WA, Hill VA (1993) Sample preparation techniques. Forensic Sci Int 63: 121–143CrossRefPubMedGoogle Scholar
  32. 33.
    Polettini A, Stramesi C, Vignali C, Montagna M (1997) Determination of opiates in hair. Effects of extraction methods on recovery and on stability of analytes. Forensic Sci Int 84: 259–269CrossRefPubMedGoogle Scholar
  33. 34.
    Romano G, Barbera N, Spadaro G, Valenti V (2003) Determination of drugs of abuse in hair: Evaluation of external heroin contamination and risk of false positives. Forensic Sci Int 131: 98–102CrossRefPubMedGoogle Scholar
  34. 35.
    Blank DL, Kidwell DA (1993) External contamination of hair by cocaine: An issue in forensic interpretation. Forensic Sci Int 63: 145–160CrossRefPubMedGoogle Scholar
  35. 36.
    Rollins DE, Wilkins DG, Krueger GG (2003) The effect of hair color on the incorporation of codeine into human hair. J Anal Toxicol 27: 545–551PubMedGoogle Scholar
  36. 37.
    Reid RW, O’Connor FL, Deakin AG, Ivery DM, Crayton JW (1996) Cocaine and metabolites in human graying hair: Pigmentary relationship. J Toxicol Clin Toxicol 34: 685–690CrossRefPubMedGoogle Scholar
  37. 38.
    Kidwell DA, Lee EH, DeLauder SF (2000) Evidence for bias in hair testing and procedures to correct bias. Forensic Sci Int 107: 39–61CrossRefPubMedGoogle Scholar
  38. 39.
    Caetano R, Cunradi C (2002) Alcohol dependence: A public health perspective. Addiction 97: 633–645CrossRefPubMedGoogle Scholar
  39. 40.
    Narahashi T, Kuriyama K, Illes P, Wirkner K, Fischer W, Mühlberg K, Scheibler P, Allgaier C, Minami K, Lovinger D, Lallemand F, Ward RJ, DeWitte P, Itatsu T, Takei Y, Oide H, Hirose M, Wang XE, Watanabe S, Tateyama M, Ochi R, Sato N (2001) Neuroreceptors and ion channels as targets of alcohol. Alcohol Clin Exp Res 25 (5 Suppl ISBRA): 182S–188SPubMedGoogle Scholar
  40. 41.
    Norberg A, Jones AW, Hahn RG, Garielsson JL (2003) Role of variability in explaining ethanol pharmacokinetics: Research and forensic applications. Clin Pharmacokinet 42: 1–31CrossRefPubMedGoogle Scholar
  41. 42.
    Edenberg HJ (2007) The genetics of alcohol metabolism: Role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 30: 5–13PubMedGoogle Scholar
  42. 43.
    Norberg A, Jones AW, Hahn RG (2003) Role of variability in explaining ethanol pharmacokinetics: Research and forensic applications. Clin Pharmacokinet 42: 1–31CrossRefPubMedGoogle Scholar
  43. 44.
    Zuba D (2008) Accuracy and reliability of breath alcohol testing by handheld electrochemical analysers. Forensic Sci Int 178: e29–33CrossRefPubMedGoogle Scholar
  44. 45.
    Trafford DJ, Makin HL (1994) Breath-alcohol concentration may not always reflect the concentration of alcohol in blood. J Anal Toxicol 18: 225–228PubMedGoogle Scholar
  45. 46.
    Rainey PM (1993) Relation between serum and whole-blood ethanol concentrations. Clin Chem 39: 2288–2292PubMedGoogle Scholar
  46. 47.
    Smolle KH, Hofmann G, Kaufmann P (1999) Q.E.D. Alcohol test: A simple and quick method to detect ethanol in saliva of patients in emergency departments. Comparison with the conventional determination in blood. Intensive Care Med 25: 492–495CrossRefPubMedGoogle Scholar
  47. 48.
    Soderberg BL, Salem RO, Best CA (2003) Fatty acid ethyl esters. Ethanol metabolites that reflect ethanol intake. Am J Clin Pathol 119: S94–99Google Scholar
  48. 49.
    Kraman P (2004) Drug Abuse in America-Rural Meth. Trends Alert. The Council of State Governments, Lexington, KY, March 2004Google Scholar
  49. 50.
    Weir E (2000) Raves: A review of the culture, the drugs, and the prevention of harm. Can Med Assoc J 162: 1829–1830Google Scholar
  50. 51.
    Chiang WK (2006) Amphetamines. In: LR Goldfrank, NE Flomenbaum, NA Lewin, MA Howland, RS Hoffman, LS Nelson (eds): Goldfrank’s Toxicologic Emergencies, 8th edn., McGraw-Hill, New York, 1118–1132Google Scholar
  51. 52.
    Cody JT (2002) Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occup Environ Med 44: 435–450CrossRefPubMedGoogle Scholar
  52. 53.
    Stout PR, Klette KL, Horn CK (2004) Evaluation of ephedrine, pseudoephedrine and phenyl-propanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. J Forensic Sci 49: 160–164CrossRefPubMedGoogle Scholar
  53. 54.
    Stout PR, Klette KL, Wiegand R (2003) Comparison and evaluation of DRI methamphetamine, DRI ecstasy, Abuscreen ONLINE amphetamine, and a modified Abuscreen ONLINE amphetamine screening immunoassays for the detection of amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) in human urine. J Anal Toxicol 27: 265–269PubMedGoogle Scholar
  54. 55.
    Paul BD, Jemionek J, Lesser D, Jacobs A, Searles DA (2004) Enantiomeric separation and quantitation of (±)-amphetamine, (±)-methamphetamine, (±)-MDA, (±)-MDMA, and (±)-MDEA in urine specimens by GC-EI-MS after derivatization with (R)-(−)-or (S)-(+)-α-methoxy-α-(trifluoromethy) phenylacetyl chloride (MTPA). J Anal Toxicol 28: 449–455PubMedGoogle Scholar
  55. 56.
    Krasowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S (2009) Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 9: 5CrossRefPubMedGoogle Scholar
  56. 57.
    Smink BE, Hofman BJ, Dijkhuizen A, Lusthof KJ, de Gier JJ, Egberts AC, Uges DR (2008) The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. Br J Clin Pharmacol 66: 556–560CrossRefPubMedGoogle Scholar
  57. 58.
    Kintz P, Tracqui A, Mangin P (1996) Sweat testing for benzodiazepines. J Forensic Sci 41: 851–854PubMedGoogle Scholar
  58. 59.
    Kintz P, Villain M, Cirimele V, Pépin G, Ludes B (2004) Windows of detection of lorazepam in urine, oral fluid and hair, with a special focus on drug-facilitated crimes. Forensic Sci Int 145: 131–135CrossRefPubMedGoogle Scholar
  59. 60.
    Verstraete AG (2004) Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit 26: 200–205CrossRefPubMedGoogle Scholar
  60. 61.
    Chéze M, Duffort G, Deveaux M, Pépin G (2005) Hair analysis by liquid chromatography-tandem mass spectrometry in toxicological investigation of drug-facilitated crimes: Report of 128 cases over the period June 2003-May 2004 in metropolitan Paris. Forensic Sci Int 153: 3–10CrossRefPubMedGoogle Scholar
  61. World Drug Report (2008) United Nations Office on Drugs and Crime (online available at: http://www.unodc.org/documents/wdr/WDR_2008/WDR_2008_eng_web.pdf; accessed March 28, 2009)Google Scholar
  62. 63.
    Chen CY, O’Brien MS, Anthony JC (2005) Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug Alcohol Depend 79: 11–22CrossRefPubMedGoogle Scholar
  63. 64.
    Elkashef A, Vocci F, Huestis M, Haney M, Budney A, Gruber A, el-Guebaly N (2008) Marijuana neurobiology and treatment. Subst Abus 29: 17–29CrossRefPubMedGoogle Scholar
  64. 65.
    Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma Δ9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28: 409–416PubMedGoogle Scholar
  65. 66.
    Musshoff F, Madea B (2006) Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit 28: 155–163CrossRefPubMedGoogle Scholar
  66. 67.
    Teixeira H, Verstraete A, Proenca P, Corte-Real F, Monsanto P, Vieira DN (2007) Validated method for the simultaneous determination of Δ9-THC and Δ9-THC-COOH in oral fluid, urine and whole blood using solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionization. Forensic Sci Int 170: 148–155CrossRefPubMedGoogle Scholar
  67. 68.
    Maralikova B, Weinmann W (2004) Simultaneous determination of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannibol in human plasma by high-performance liquid chromatography/tandem mass spectrometry. J Mass Spectrom 39: 526–531CrossRefPubMedGoogle Scholar
  68. 69.
    Huestis MA, Cone EJ (2004) Relationship of Δ9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 28: 394–399PubMedGoogle Scholar
  69. 70.
    Cone EJ, Huestis MA (1993) Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit 15: 527–532CrossRefPubMedGoogle Scholar
  70. 71.
    Huestis MA, Henningfield JE, Cone EJ (1992) Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Δ9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 16: 283–290PubMedGoogle Scholar
  71. 72.
    Giroud C, Ménétrey A, Augsburger M, Buclin T, Sanchez-Mazas P, Mangin P (2001) Δ9-THC, 11-OH-Δ9-THC and Δ9-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int 123: 159–164CrossRefPubMedGoogle Scholar
  72. 73.
    Skopp G, Pötsch L, Mauden M, Richter B (2002) Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-Δ9-carboxy tetrahydrocannabinol glucuronide. Forensic Sci Int 126: 17–23CrossRefPubMedGoogle Scholar
  73. 74.
    Huestis MA, Henningfield JE, Cone EJ (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16: 276–282PubMedGoogle Scholar
  74. 75.
    Kielland KB (1992) [Urinary excretion of cannabis metabolites]. Tidsskr Nor Laegeforen 112: 1585–1586PubMedGoogle Scholar
  75. 76.
    Lafolie P, Beck O, Blennow G, Boréus L, Borg S, Elwin CE, Karlsson L, Odelius G, Hjemdahl P (1991) Importance of creatinine analyses of urine when screening for abused drugs. Clin Chem 37: 1927–1931PubMedGoogle Scholar
  76. 77.
    Fraser AD, Worth D (1999) Urinary excretion profiles of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol: a Δ9-THCCOOH to creatinine ratio study. J Anal Toxicol 23: 531–534PubMedGoogle Scholar
  77. 78.
    Manno JE, Manno BR, Kemp PM, Alford DD, Abukhalaf IK, McWilliams, ME, Hagaman FN, Fitzgerald MJ (2001) Temporal indication of marijuana use can be estimated from plasma and urine concentrations of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 25: 538–549PubMedGoogle Scholar
  78. 79.
    Golding Fraga S, Diaz-Flores Estevez J, Diaz Romero C (1998) Stability of cannabinoids in urine in three storage temperatures. Ann Clin Lab Sci 28: 160–162PubMedGoogle Scholar
  79. 80.
    Nakahara Y, Takahashi K, Kikura R (1995) Hair analysis for drugs of abuse. X. Effect of physicochemical properties of drugs on the incorporation rates into hair. Biol Pharm Bull 18: 1223–1227PubMedGoogle Scholar
  80. 81.
    Musshoff F, Driever F, Lachenmeier K, Lachenmeier DW, Banger W, Madea B (2006) Results of hair analyses for drugs of abuse and comparison with self-reports and urine tests. Forensic Sci Int 156: 118–123CrossRefPubMedGoogle Scholar
  81. 82.
    Uhl M (2000) Tandem mass spectrometry: A helpful tool in hair analysis for the forensic expert. Forensic Sci Int 107: 169–179CrossRefPubMedGoogle Scholar
  82. 83.
    Samyn N, De Boeck G, Verstraete AG (2002) The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. J Forensic Sci 47: 1380–1387PubMedGoogle Scholar
  83. 84.
    Crouch DJ, Walsh JM, Cangianelli L, Quintela (2008) Laboratory evaluation and field application of roadside oral fluid collectors and drug testing devices. Ther Drug Monit 30: 188–195CrossRefPubMedGoogle Scholar
  84. 85.
    World situation with regard to drug abuse— Report by the secretariat. United Nations Economic and Social Council Commission on Narcotic Drugs (online available at: http://daccess-ods.un.org/TMP/648688.html; accessed May 19, 2009)Google Scholar
  85. 86.
    The NSDUH Report — Cocaine Use: 2002 and 2003: Substance Abuse and Mental Health Services Administration (SAMHSA) (online available, at: http://www.oas.samhsa.gov/2k5/cocaine/cocaine.pdf; accessed May 19, 2009)Google Scholar
  86. 87.
    Jacob P 3rd, Jones RT, Benowitz NL, Shulgin AT, Lewis ER, Elias-Baker BA (1990) Cocaine smokers excrete a pyrolysis product, anhydroecgonine methyl ester. J Toxicol Clin Toxicol 28: 121–125CrossRefPubMedGoogle Scholar
  87. 88.
    Toennes SW, Fandino AS, Kauert G (1999) Gas chromatographic-mass spectrometric detection of anhydroecgonine methyl ester (methylecgonidine) in human serum as evidence of recent smoking of crack. J Chromatogr B Biomed Sci Appl 735: 127–132CrossRefPubMedGoogle Scholar
  88. 89.
    Paul BD, McWhorter LK, Smith ML (1999) Electron ionization mass fragmentometric detection of urinary ecgonidine, a hydrolytic product of methylecgonidine, as an indicator of smoking cocaine. J Mass Spectrom 34: 651–660CrossRefPubMedGoogle Scholar
  89. 90.
    Linder MW, Bosse GM, Henderson MT, Midkiff G, Valdes R (2000) Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clin Chim Acta 295: 179–185CrossRefPubMedGoogle Scholar
  90. 91.
    Cone EJ, Sampson-Cone AH, Darwin WD, Huestis MA, Oyler JM (2003) Urine testing for cocaine abuse: Metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol 27: 386–401PubMedGoogle Scholar
  91. 92.
    Felli M, Martello S, Marsili R, Chiarotti M (2005) Disappearance of cocaine from human hair after abstinence. Forensic Sci Int 154: 96–98CrossRefPubMedGoogle Scholar
  92. 93.
    Shah JC, Mason WD (1990) Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. J Clin Pharmacol 30: 764–766PubMedGoogle Scholar
  93. 94.
    Moriya F, Chan KM, Hashimoto Y (1999) Concentrations of morphine and codeine in urine of heroin abusers. Leg Med (Tokyo) 1: 140–144Google Scholar
  94. 95.
    Rook EJ, Huitema AD, van den Brink W, Hillebrand MJ, van Ree JM, Beijnen JH (2006) Screening for illicit heroin use in patients in a heroin-assisted treatment program. J Anal Toxicol 30: 390–394PubMedGoogle Scholar
  95. 96.
    Compton WM, Volkow ND (2006) Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 81: 103–107CrossRefPubMedGoogle Scholar
  96. 97.
    Rohrig TP, Moore C (2003) The determination of morphine in urine and oral fluid following ingestion of poppy seeds. J Anal Toxicol 27: 449–452PubMedGoogle Scholar
  97. 98.
    Ceder G, Jones AW (2001) Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. Clin Chem 47: 1980–1984PubMedGoogle Scholar
  98. 99.
    Romano G, Barbera N, Spadaro G, Valenti V (2003) Determination of drugs of abuse in hair: Evaluation of external heroin contamination and risk of false positives. Forensic Sci Int 131: 98–102CrossRefPubMedGoogle Scholar
  99. 100.
    Hill V, Cairns T, Cheng CC, Schaffer M (2005) Multiple aspects of hair analysis for opiates: Methodology, clinical and workplace populations, codeine, and poppy seed ingestion. J Anal Toxicol 29: 696–703PubMedGoogle Scholar
  100. 101.
    The DASIS Report Trends in Admissions for PCP: 1993–2003. Substance Abuse & Mental Health Services Administration (SAMHSA) (online available at: http://www.oas.samhsa.gov/2k5/PCPtx/PCPtx.htm; accessed May 19, 2009)Google Scholar
  101. 102.
    Santos PM, López-García P, Navarro JS, Fernández AS, Sádaba B, Vidal JP (2007) False positive phencyclidine results caused by venlafaxine. Am J Psychiatry 164: 349CrossRefPubMedGoogle Scholar
  102. 103.
    Schier J (2000) Avoid unfavorable consequences: Dextromethorpan can bring about a false-positive phencyclidine urine drug screen. J Emerg Med 18: 379–381CrossRefPubMedGoogle Scholar
  103. 104.
    Moeller KE, Lee KC, Kissack JC (2008) Urine drug screening: practical guide for clinicians. Mayo Clin Proc 2008 83: 66–76CrossRefGoogle Scholar
  104. 105.
    Kala SV, Harris SE, Freijo TD, Gerlich S (2008) Validation of analysis of amphetamines, opiates, phencyclidine, cocaine, and benzoylecgonine in oral fluids by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 32: 605–611PubMedGoogle Scholar
  105. 106.
    Nakahara Y, Takahashi K, Sakamoto T, Tanaka A, Hill VA, Baumgartner WA (1997) Hair analysis for drugs of abuse. XVII. Simultaneous detection of PCP, PCHP, and PCPdiol in human hair for confirmation of PCP use. J Anal Toxicol 21: 356–362PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2010

Authors and Affiliations

  • David Vearrier
    • 1
  • John A. Curtis
    • 1
  • Michael I. Greenberg
    • 1
  1. 1.Department of Emergency Medicine, Division of Medical ToxicologyDrexel University College of MedicinePhiladelphiaUSA

Personalised recommendations